Jim Simons
INM icon

Jim Simons’s InMed Pharmaceuticals INM Stock Holding History

Jim Simons’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,800
Closed -$36.8K – 3483
2025
Q3 		$36.8K Buy
+16,800
New +$40.5K ﹤0.01% 3380
2024
Q4 		– Sell
-2,515
Closed -$11.9K – 3727
2024
Q3 		$11.9K Buy
+2,515
New +$12.8K ﹤0.01% 3453
2024
Q2 		– Sell
-1,415
Closed -$10K – 3721
2024
Q1 		$10K Sell
1,415
-530
-27% -$3.9K ﹤0.01% 3623
2023
Q4 		$16K Buy
+1,945
New +$18.9K ﹤0.01% 3603
2023
Q2 		– Sell
-3,875
Closed -$84K – 4082
2023
Q1 		$84K Buy
+3,875
New +$125K ﹤0.01% 3540
2022
Q3 		– Sell
-99
Closed -$23K – 4213
2022
Q2 		$23K Buy
99
+9
+10% +$3.44K ﹤0.01% 4105
2022
Q1 		$43K Buy
90
+2
+2% +$1.05K ﹤0.01% 3931
2021
Q4 		$58K Buy
+88
New +$68.1K ﹤0.01% 3768

Other funds holding INM

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Jim Simons's INM Position: Q4 2025 in Review

Jim Simons sold out of InMed Pharmaceuticals (INM) in Q4 2025, closing a stake of 16,800 shares — an estimated $36.8K sold.

Jim Simons first reported a position in INM in Q4 2021 and held it in 8 quarters. The position peaked at $84K in Q1 2023. 7 funds tracked by Wall St. Rank hold INM as of Q4 2025.

  • Jim Simons reported no remaining InMed Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jim Simons sold 16,800 InMed Pharmaceuticals shares in Q4 2025, an estimated $36.8K.
  • Jim Simons first reported a position in InMed Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Jim Simons's InMed Pharmaceuticals position peaked at $84K in Q1 2023.
  • 7 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.